POZ Community Forums

Meds, Mind, Body & Benefits => Questions About Treatment & Side Effects => Topic started by: vertigo on August 13, 2013, 06:45:38 pm

Title: Dolutegravir approval
Post by: vertigo on August 13, 2013, 06:45:38 pm

The FDA approved the new integrase inhibitor dolutegravir yesterday.  It will be marketed as Tivicay:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm

This drug is going to be big.  The first once-daily, unboosted integrase inhibitor.  Basically Isentress but only one time a day.  Dr Paul Sax has been pretty keen on it for a while:

http://blogs.jwatch.org/hiv-id-observations/

I think we're going to hear a lot more about this, particularly once it gets formulated into single-tablet regimens.

Title: Re: Dolutegravir approval
Post by: oksikoko on August 13, 2013, 08:00:23 pm

Someone please get me a job in the branding department of one of these companies. First "Stribild" now "Tivicay"? I want it, though, if it doesn't come with cobicistat.

Marketing aside, does anyone know where the real names come from? I see inTEGRAse and VIRus in there, but what's a "dolu", an "elvi" and a "ral"?

Sincerely,
Lee, focusing on what's really important here since 1976

Title: Re: Dolutegravir approval
Post by: Ann on August 14, 2013, 06:32:19 am

Quote from: vertigo on August 13, 2013, 06:45:38 pm

This drug is going to be big. 

I agree. My doctor (aka the Wizard of Poz - he's also an hiv pharmacologist with years of med research under his belt) has been really excited about this med, and he doesn't get excited very easily. :)

Title: Re: Dolutegravir approval
Post by: Matts on August 14, 2013, 07:58:44 am

Prescribing and Dosage Information are available:
http://www.viivhealthcare.com/media/58599/us_tivicay.pdf (http://www.viivhealthcare.com/media/58599/us_tivicay.pdf)

The side effects seem to be low. It can make problems with Hep B or C coinfections.

And "Coadministration of TIVICAY with dofetilide is contraindicated due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events."
[see Drug Interactions (7)].